Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib’s efficacy

A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval – Pharmaceutical Technology

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 20, 2024

Five things FDA ad comm members want

As a public health professional, I want people to have access to the health care they need to improve their quality of life. For years

October 1, 2024

Temporary nurse staffing partially combats increased risk of patient deaths

A new study led by the University of Southampton has found that using temporary nursing staff to fill rotas only partially combats an increased risk

August 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.